Ikena Oncology, Inc. (IKNA)

1.1500

+0.0200

+(1.77%)

As of 9:55:37 AM EDT. Market Open.

Traws Pharma Announces Management Updates

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer

GlobeNewswire last month

IOVA

IKNA
+1.77%

TRAW
Discovering February 2025's Promising Penny Stocks On US Exchanges

As the S&P 500 hovers near record highs and Treasury yields drop following recent retail sales data, U.S. markets continue to capture investor attention with a mix of optimism and caution. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing segment for those seeking unique investment opportunities. Despite the term's historical connotations, these stocks can offer hidden value when supported by strong financials and growth potential. This article...

Simply Wall St. 2 months ago

IKNA
+1.77%

MCHX

SLDP
US Penny Stocks To Watch In January 2025

As the new year begins, major U.S. stock indices have extended their recent slump, with the Dow Jones Industrial Average and S&P 500 both experiencing declines. Despite these broader market challenges, penny stocks—often representing smaller or newer companies—remain an area of interest for investors seeking growth opportunities. While the term "penny stock" may seem outdated, these investments can still offer significant potential when backed by strong financials.

Simply Wall St. 4 months ago

TOUR

IKNA
+1.77%

NHTC
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade

Ikena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 months ago

IKNA
+1.77%
Ikena Oncology and Inmagene Announce Merger and Fundraising

Ikena Oncology ( (IKNA) ) has provided an announcement. Ikena Oncology and Inmagene Biopharmaceuticals have announced a definitive merger agreement, under which the combined company will focus on developing IMG-007, a monoclonal antibody aimed at treating atopic dermatitis and other inflammatory conditions. The transaction involves a private placement raising approximately $175 million, including $75 million from new and existing investors, and is expected to close in mid-2025. Following the mer

TipRanks 4 months ago

IKNA
+1.77%
Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks were higher late Monday afternoon, with the NYSE Health Care Index rising 0.9% an

PREMIUM
MT Newswires 4 months ago

IKNA
+1.77%
Ikena Oncology, Inmagene Sign Merger Deal; Shares Rise

Ikena Oncology (IKNA) and clinical-stage biotechnology company Inmagene Biopharmaceuticals said Mond

PREMIUM
MT Newswires 4 months ago

IKNA
+1.77%
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger The Financing includes both new investors such as Deep Track Capital, Foresite Capital,

GlobeNewswire 4 months ago

IKNA
+1.77%
3 US Penny Stocks With Market Caps Over $40M To Consider

As the U.S. stock market takes a breather following a post-election rally, investors are keenly observing opportunities that might arise in different sectors. Penny stocks, despite their somewhat outdated name, remain relevant as they often represent smaller or newer companies with potential for growth. With strong financial foundations and solid fundamentals, these stocks can offer valuable opportunities for those willing to explore beyond the well-trodden paths of larger firms.

Simply Wall St. 5 months ago

IKNA
+1.77%

MNOV

RLYB
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023)

Ikena Oncology ( NASDAQ:IKNA ) Third Quarter 2024 Results Key Financial Results Net loss: US$10.2m (loss narrowed by...

Simply Wall St. 5 months ago

IKNA
+1.77%
Ikena Oncology Reports Third Quarter 2024 Financial Results

Strong financial position with $138 million in cash and investments at close of third quarterBOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided an update regarding its ongoing activities. Pipeline and Corporate Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared

GlobeNewswire 6 months ago

IKNA
+1.77%
Ikena Oncology Reports Second Quarter 2024 Financial Results

Strong financial position with $145 million in cash and investments at close of second quarterBOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety eval

GlobeNewswire 8 months ago

IKNA
+1.77%
Best Momentum Stocks to Buy for July 12th

IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.

Zacks 9 months ago

IKNA
+1.77%

AVAH

VEL
It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year

Key Insights Ikena Oncology's Annual General Meeting to take place on 7th of June CEO Mark Manfredi's total...

Simply Wall St. 11 months ago

IKNA
+1.77%
UPDATE – Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development

GlobeNewswire 11 months ago

IKNA
+1.77%
Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development

GlobeNewswire 11 months ago

IKNA
+1.77%
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provi

GlobeNewswire 11 months ago

IKNA
+1.77%

Performance Overview

Return	IKNA	S&P 500 (^GSPC)
YTD	-29.88%	-1.21%
1-Year	-10.85%	+11.25%
3-Year	-69.25%	+47.84%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TARIFFS LATEST

Ikena Oncology, Inc. (IKNA)

Traws Pharma Announces Management Updates

Discovering February 2025's Promising Penny Stocks On US Exchanges

US Penny Stocks To Watch In January 2025

Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade

Ikena Oncology and Inmagene Announce Merger and Fundraising

Sector Update: Health Care Stocks Advance Late Afternoon

Ikena Oncology, Inmagene Sign Merger Deal; Shares Rise

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

3 US Penny Stocks With Market Caps Over $40M To Consider

Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023)

Ikena Oncology Reports Third Quarter 2024 Financial Results

Ikena Oncology Reports Second Quarter 2024 Financial Results

Best Momentum Stocks to Buy for July 12th

It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year

UPDATE – Ikena Oncology Announces Strategic Update

Ikena Oncology Announces Strategic Update

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Performance Overview